{
    "clinical_study": {
        "@rank": "136303", 
        "arm_group": [
            {
                "arm_group_label": "generic bupropion IR75", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion IR75"
            }, 
            {
                "arm_group_label": "generic bupropion IR100", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion IR100"
            }, 
            {
                "arm_group_label": "generic bupropion SR100", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion SR100"
            }, 
            {
                "arm_group_label": "generic bupropion SR150", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion SR150"
            }, 
            {
                "arm_group_label": "generic bupropion XL150", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion XL150"
            }, 
            {
                "arm_group_label": "generic bupropion XL300", 
                "arm_group_type": "Active Comparator", 
                "description": "One oral dose of generic bupropion XL300"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this project are to determine if the bioavailability and release pattern\n      of bupropion HCl products differ and if the genotype of the metabolic enzymes affects the\n      saturation of intestinal enzymes with different dose strengths within one product line.\n      Findings from this project will help the FDA Center for Drug Evaluation and Research's\n      (CDER) Office of Generic Drugs improve policy development and review practice in the future\n      for similar products, e.g. extended release oral drug products being metabolized in the gut\n      wall and having multiple strengths.\n\n      Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy\n      individuals when they ingest different strengths of bupropion (75-300 mg) with variable\n      release profiles (IR vs XL vs SR) in GI tract.\n\n      Working hypothesis: Variation in release rate and mechanism of bupropion formulations in\n      gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract,\n      which will generate different concentration of bupropion and its metabolites in plasma.\n\n      Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation,\n      and pharmacokinetics of bupropion\n\n      Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22)  in patients\n      will increase the metabolism of bupropion in the GI tract and liver, reduce both local\n      concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when\n      bupropion is released earlier in GI tract"
        }, 
        "brief_title": "Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns", 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers 25 to 55 years old.\n\n          -  Volunteers have a Body Mass Index (BMI), calculated from the ratio of height and\n             weight, within a range of 18.5 to 35.\n\n          -  Willing to be medication and supplement free 2 weeks prior to beginning study, and\n             throughout the study. All forms of birth control are okay.\n\n        Exclusion Criteria:\n\n          -  Individuals unwilling or unable to comply with the study protocol (e.g. unable to\n             remain medication or supplement free during the study).\n\n          -  Individuals unwilling or unable to take bupropion or have an allergy to bupropion\n\n          -  Any medical or surgical conditions which might significantly alter bupropion\n             absorption (e.g., history of malabsorption, liver disease, gastric bypass surgery )\n\n          -  Individuals with a history of psychiatric or neurological illness, including seizure\n             disorders\n\n          -  Nicotine dependence\n\n          -  Alcohol dependence\n\n          -  Pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078180", 
            "org_study_id": "HHSF223201310164C", 
            "secondary_id": "HUM00081894"
        }, 
        "intervention": {
            "arm_group_label": [
                "generic bupropion IR75", 
                "generic bupropion IR100", 
                "generic bupropion SR100", 
                "generic bupropion SR150", 
                "generic bupropion XL150", 
                "generic bupropion XL300"
            ], 
            "intervention_name": "generic bupropion", 
            "intervention_type": "Drug", 
            "other_name": "Wellbutrin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bupropion"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109-2700"
                }, 
                "name": "University of Michigan"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns", 
        "overall_contact": {
            "email": "bpresearch@umich.edu", 
            "last_name": "Gloria Harrington", 
            "phone": "877-864-3637"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Duxin Sun, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For each drug formulation we will collect a PK sample at each time point.  We will use this composite of data (all time points for each formulation) to model Pharmacokinetic parameters such as half-life (t1/2), volume of distribution (Vd/F), oral clearance (CL/F), maximum drug concentration (Cmax), time to reach Cmax (Tmax), area under the concentration vs. time curve (AUC), absorption rate constant.  However, we will do each formulation separately (not as a composite).", 
            "measure": "PK parameters for bupropion formulations: half-life (t1/2), volume of distribution (Vd/F), oral clearance (CL/F), maximum drug concentration (Cmax), time to reach Cmax (Tmax), area under the concentration vs. time curve (AUC), absorption rate constant", 
            "safety_issue": "No", 
            "time_frame": "Pharmacokinetic (PK) data will be collected over time points:  0, 0.5, 1, 2, 3, 4, 6, 8, 12*, 24, 48, 72, and 96 hours post-dose. *XL formulation only."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078180"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan", 
            "investigator_full_name": "Duxin Sun", 
            "investigator_title": "Professor of Pharmaceutical Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Michigan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}